Preparation of injectable suspensions having improved injectability
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/14
A61F-013/00
A61F-002/00
출원번호
US-0681142
(2003-10-09)
등록번호
US-7371406
(2008-05-13)
발명자
/ 주소
Ramstack,J. Michael
Riley,M. Gary I.
Zale,Stephen E.
Hotz,Joyce M.
Johnson,Olufunmi L.
출원인 / 주소
Alkermes Controlled Therapeutics, Inc.
대리인 / 주소
Reister,Andrea G.
인용정보
피인용 횟수 :
15인용 특허 :
43
초록▼
Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20�� C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension sign
Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20�� C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability.
대표청구항▼
What is claimed is: 1. A method for preparing a composition suitable for injection through a needle into a host, comprising: (a) mixing dry microparticles with an injection vehicle to form a first suspension, wherein the microparticles comprise a polymeric binder and wherein the microparticles are
What is claimed is: 1. A method for preparing a composition suitable for injection through a needle into a host, comprising: (a) mixing dry microparticles with an injection vehicle to form a first suspension, wherein the microparticles comprise a polymeric binder and wherein the microparticles are suspended in the injection vehicle at a concentration of from about 175 mg/ml to about 400 mg/ml; and (b) mixing the first suspension with a viscosity enhancing agent to form a second suspension, wherein the viscosity enhancing agent increases viscosity of a fluid phase of the second suspension to be in the range of from about 20 cp to about 600 cp at 20�� C., wherein the viscosity of the fluid phase of the second suspension provides injectability of the composition into the host through a needle ranging in diameter from 18-22 gauge. 2. The method of claim 1, wherein the viscosity of the fluid phase of the second suspension after step (b) is from about 200 cp to about 600 cp at 20�� C. 3. The method of claim 1, wherein the concentration of microparticles in the first suspension is greater than about 300 mg/ml and less than about 400 mg/ml. 4. The method of claim 1, wherein a viscosity of the viscosity enhancing agent is from about 1000 to about 2000 cp at 20�� C. 5. The method of claim 1, wherein the viscosity enhancing agent comprises sodium carboxymethyl cellulose. 6. The method of claim 1, wherein a volume of the viscosity enhancing agent mixed with the first suspension is approximately 10-25% of the volume of the first suspension. 7. The method of claim 1, further comprising before step (b): (c) withdrawing the first suspension into a first syringe. 8. The method of claim 7, wherein step (b) comprises: (i) providing a second syringe containing the viscosity enhancing agent; (ii) coupling the first syringe to the second syringe so that fluid can pass between the first and second syringes; and (iii) repeatedly passing the first suspension and the viscosity enhancing agent between the first and second syringes. 9. A method for administering a composition to a host, comprising: (a) mixing dry microparticles with an injection vehicle to form a first suspension, wherein the microparticles comprise a polymeric binder and wherein the microparticles are suspended in the injection vehicle at a concentration of from about 175 mg/ml to about 400 mg/ml; (b) mixing the first suspension with a viscosity enhancing agent to form a second suspension, wherein the viscosity enhancing agent increases viscosity of a fluid phase of the second suspension to be in the range of from about 20 cp to about 600 cp at 20�� C. wherein the viscosity of the fluid phase of the second suspension provides injectability of the composition into the host; and (c) injecting the second suspension into the host through a needle ranging in diameter from 18-22 gauge. 10. A method for administering a composition to a host, comprising: (a) mixing dry microparticles with an injection vehicle to form a suspension, wherein the injection vehicle has a viscosity at 20�� C. of less than about 60 cp, wherein the microparticles comprise a polymeric binder and wherein the microparticles are suspended in the injection vehicle at a concentration of from about 175 mg/ml to about 400 mg/ml; (b) changing the viscosity of a fluid phase of the suspension to be in the range of from about 20 cp to about 600 cp at 20�� C. wherein the viscosity of the fluid phase of the second suspension provides injectability of the composition into the host; (c) withdrawing the suspension into a syringe; and (d) injecting the suspension from the syringe into the host through a needle ranging in diameter from 18-22 gauge. 11. The method of claim 10, wherein step (b) comprises: changing the temperature of the fluid phase of the suspension. 12. The method of claim 10, wherein step (c) is performed prior to step (b), and step (b) comprises: adding a viscosity enhancing agent to the suspension in the syringe to thereby increase the viscosity of the fluid phase of the suspension. 13. The method of claim 12, wherein the viscosity enhancing agent comprises sodium carboxymethyl cellulose. 14. The method of claim 9, wherein the microparticles comprise an active agent. 15. A method of making a composition suitable for injection through a needle into a host, comprising: (a) providing microparticles comprising a polymeric binder; (b) providing an injection vehicle having a viscosity of at least 20 cp at 20�� C.; and (c) suspending the microparticles in the injection vehicle to form a suspension, wherein the microparticles are suspended in the injection vehicle at a concentration of from about 175 mg/ml to about 400 mg/ml, wherein the viscosity of a fluid phase of the suspension is in the range of from about 20 cp to about 600 cp at 20�� C., wherein the viscosity of the fluid phase of the suspension provides injectability of the composition into the host through a needle ranging in diameter from 18-22 gauge. 16. The method of claim 10, wherein step (c) is performed prior to step (b). 17. A method for preparing a composition suitable for injection through a needle into a host, comprising: (a) mixing dry microparticles with an injection vehicle to form a first suspension, wherein the microparticles comprise a polymeric binder and wherein the microparticles are suspended in the injection vehicle at a concentration of from about 175 mg/ml to about 400 mg/ml; and (b) mixing the first suspension with a viscosity enhancing agent to form a second suspension, wherein the viscosity enhancing agent increases viscosity of a fluid phase of the second suspension to be in the range of from about 20 cp to about 600 cp at 20�� C., wherein the viscosity of the fluid phase of the second suspension provides injectability of the composition into the host through a needle of medically acceptable size. 18. The method of claim 17, wherein an internal diameter of the needle ranges from about 700 to about 400 microns. 19. A method of making a composition suitable for injection through a needle into a host, comprising: suspending microparticles comprising a polymeric binder in an injection vehicle having a viscosity of at least 20 cp at 20�� C. to form a suspension, wherein the microparticles are suspended in the injection vehicle at a concentration of from about 175 mg/ml to about 400 mg/ml, wherein the viscosity of a fluid phase of the suspension is in the range of from about 20 cp to about 600 cp at 20�� C., wherein the viscosity of the fluid phase of the suspension provides injectability of the composition into the host through a needle of medically acceptable size. 20. The method of claim 19, wherein an internal diameter of the needle ranges from about 700 to about 400 microns.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (43)
Cho-Chung Yoon S. (7017 Kenhill Rd. Bethesda MD 20817), Antisense oligonucleotides of human regulatory subunit RI-aof camp dependent pro.
Fran.cedilla.ois Marc Karel Jozef,BEX ; Embrechts Roger Carolus Augusta,BEX ; Borghijs Herman Karel,BEX ; Monbaliu Johan,BEX, Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters.
Fran.cedilla.ois, Marc Karel Jozef; Dries, Willy Maria Albert Carlo; Basstanie, Esther Dina Guido, Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters.
Johnson OluFunmi Lily (Cambridge MA) Ganmukhi Medha M. (Wexford PA) Bernstein Howard (Cambridge MA) Auer Henry (Belmont MA) Khan M. Amin (Dowington PA), Composition for sustained release of human growth hormone.
Johnson OluFunmi Lily (Cambridge MA) Ganmukhi Medha M. (Wexford PA) Bernstein Howard (Cambridge MA) Auer Henry (Belmont MA) Khan M. Amin (Dowington PA), Composition for sustained release of human growth hormone.
Kitchell Judith P. (Newton MA) Muni Indu A. (N. Reading MA) Boyer Yvonne N. (Salem MA), Controlled, sustained release delivery system for treating drug dependency.
Wallace Donald G. (Menlo Park CA) Reihanian Hertsel (San Francisco CA) Pharriss Bruce B. (Palo Alto CA) Braun William G. (Los Altos CA), Injectable implant composition having improved intrudability.
Tice Thomas R. ; Staas Jay K. ; Ferrell Teresa M., Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol.
Thomas R. Tice ; Jay K. Staas ; Teresa M. Ferrell ; Peter Markland, Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances.
Tice Thomas R. (Birmingham AL) Lewis Danny H. (Gardendale AL) Cowsar Donald R. (Birmingham AL) Beck Lee R. (Birmingham AL), Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents.
Mesens Jean (Wechelderzande BEX) Rickey Michael E. (Loveland OH) Atkins Thomas J. (Cincinnati OH), Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and.
Bernstein Howard (Cambridge MA) Zhang Yan (Cambridge MA) Khan M. Amin (Downingtown PA) Tracy Mark A. (Arlington MA), Modulated release from biocompatible polymers.
Ramstack J. Michael (Lebanon OH) Herbert Paul F. (Wayland MA) Strobel Jan (Westchester OH) Atkins Thomas J. (Cincinnati OH), Preparation of biodegradable microparticles containing a biologically active agent.
Rickey Michael E. ; Ramstack J. Michael ; Lewis Danny H., Preparation of biodegradable, biocompatible microparticles containing a biologically active agent.
Rickey Michael E. ; Ramstack J. Michael ; Lewis Danny H. ; Mesens Jean,BEX, Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent.
J. Michael Ramstack ; M. Gary I. Riley ; Stephen E. Zale ; Joyce M. Hotz ; Olufunmi L. Johnson, Preparation of injectable suspensions having improved injectability.
Wantier Henri (Dour BEX) Mathieu Fabienne (Nivelles BEX) Baudrihaye Marc (Waterloo BEX) Delacroix Dominique (Kraainem BEX), Preparation of microparticles for controlled release of water-soluble substances.
Kino Shigemi (Fukuoka JPX) Osajima Tomonori (Fukuoka JPX) Mizuta Hiroaki (Fukuoka JPX), Sustained release microsphere preparation containing antipsychotic drug and production process thereof.
Houchin, Mary L.; Lee, Robin H.; Qi, Hong; Oehrtman, Greg; Jennings, Robert N.; Coleman, Scott H., Sustained release formulations using non-aqueous carriers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.